Clinical trial
Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing…
NCT00335504 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00335504 |
|---|---|
| Title | Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia |
| Official title | Randomized, Phase II Trial of Atorvastatin, RAFTILOSE Synergy 1, and Sulindac Among Patients at Increased Risk for Sporadic Colorectal Neoplasia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colon Cancer, Precancerous Condition, Rectal Cancer |
| Intervention type | Drug, Other |
| Interventions | oligofructose-enriched inulin, sulindac, placebo, atorvastatin calcium, laboratory biomarker analysis |
| Enrollment | 85 |
| Start date | Mar 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Jun 12, 2006 |
| Last update posted | Feb 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: